001     1032444
005     20250203133219.0
024 7 _ |a 10.1186/s13195-024-01597-3
|2 doi
024 7 _ |a 10.34734/FZJ-2024-06250
|2 datacite_doi
024 7 _ |a 39402637
|2 pmid
024 7 _ |a WOS:001331211400001
|2 WOS
037 _ _ |a FZJ-2024-06250
082 _ _ |a 610
100 1 _ |a Pils, Marlene
|0 P:(DE-Juel1)171619
|b 0
|e First author
|u fzj
245 _ _ |a Elevated Aβ aggregates in feces from Alzheimer’s disease patients: a proof-of-concept study
260 _ _ |a London
|c 2024
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1736328900_5685
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a sFIDA was supported by the programs “Biomarkers Across Neurodegenerative Diseases I + II” of The Alzheimer’s Association, Alzheimer’s Research UK, and the Weston Brain Institute [11084, BAND-19-614337]. We are also grateful for support from The Michael J. Fox Foundation for Parkinson’s Research [14977, 009889], the ALS Association, and the Packard Center [19-SI-476]. We received further funding from the Deutsche Forschungsgemeinschaft [INST 208/616-1 FUGG, INST 208/794-1 FUGG], Helmholtz Association [HVF0079], Förderstiftung Dierichs, and Deutsche Alzheimer Gesellschaft e.V. Selbsthilfe Demenz (DalzG). G.R.F. and O.A.O. were supported by the Marga and Walter Boll-Foundation. H.G. was supported by the Cologne Clinician Scientist Program (CCSP) / Faculty of Medicine / University of Cologne and received funding from Deutsche Forschungsgemeinschaft [DFG, FI 773/15 − 1].Open Access funding enabled and organized by Projekt DEAL.
520 _ _ |a BackgroundMisfolding and aggregation of amyloid β (Aβ), along with neurofibrillary tangles consisting of aggregated Tau species, are pathological hallmarks of Alzheimer’s disease (AD) onset and progression. In this study, we hypothesized the clearance of Aβ aggregates from the brain and body into the gut.MethodsTo investigate this, we used surface-based fluorescence intensity distribution analysis (sFIDA) to determine the Aβ aggregate concentrations in feces from 26 AD patients and 31 healthy controls (HC).ResultsAβ aggregates were detectable in human feces and their concentrations were elevated in AD patients compared to HC (specificity 90.3%, sensitivity 53.8%).ConclusionThus, fecal Aβ aggregates constitute a non-invasive biomarker candidate for diagnosing AD. Whether digestion-resistant Aβ aggregates in feces are secreted via the liver and bile or directly from the enteric neuronal system remains to be elucidated.
536 _ _ |a 5251 - Multilevel Brain Organization and Variability (POF4-525)
|0 G:(DE-HGF)POF4-5251
|c POF4-525
|f POF IV
|x 0
536 _ _ |a 5244 - Information Processing in Neuronal Networks (POF4-524)
|0 G:(DE-HGF)POF4-5244
|c POF4-524
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Dybala, Alexandra
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Schaffrath, Anja
|0 P:(DE-Juel1)176527
|b 2
700 1 _ |a Rehn, Fabian
|0 P:(DE-Juel1)190725
|b 3
|u fzj
700 1 _ |a Kutzsche, Janine
|0 P:(DE-Juel1)159137
|b 4
|u fzj
700 1 _ |a Blömeke, Lara
|0 P:(DE-Juel1)177730
|b 5
|u fzj
700 1 _ |a Tusche, Markus
|0 P:(DE-Juel1)131709
|b 6
|u fzj
700 1 _ |a Özdüzenciler, Pelin
|0 P:(DE-Juel1)187484
|b 7
|u fzj
700 1 _ |a Bujnicki, Tuyen
|0 P:(DE-Juel1)162212
|b 8
|u fzj
700 1 _ |a Kraemer-Schulien, Victoria
|0 P:(DE-Juel1)172001
|b 9
|u fzj
700 1 _ |a Gramespacher, Hannes
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Schmieschek, Maximilian H. T.
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Barbe, Michael T.
|0 P:(DE-Juel1)131613
|b 12
700 1 _ |a Onur, Oezguer A.
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Fink, Gereon R.
|0 P:(DE-Juel1)131720
|b 14
|u fzj
700 1 _ |a Tamgüney, Gültekin
|0 P:(DE-Juel1)177986
|b 15
|u fzj
700 1 _ |a Bannach, Oliver
|0 P:(DE-Juel1)157832
|b 16
|u fzj
700 1 _ |a Willbold, Dieter
|0 P:(DE-Juel1)132029
|b 17
|e Corresponding author
|u fzj
773 _ _ |a 10.1186/s13195-024-01597-3
|g Vol. 16, no. 1, p. 223
|0 PERI:(DE-600)2506521-X
|n 1
|p 223
|t Alzheimer's research & therapy
|v 16
|y 2024
|x 1758-9193
856 4 _ |u https://juser.fz-juelich.de/record/1032444/files/PDF.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:1032444
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)171619
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)190725
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)159137
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)177730
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)131709
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)187484
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)162212
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 9
|6 P:(DE-Juel1)172001
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 14
|6 P:(DE-Juel1)131720
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 15
|6 P:(DE-Juel1)177986
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 16
|6 P:(DE-Juel1)157832
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 17
|6 P:(DE-Juel1)132029
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5251
|x 0
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-524
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Molecular and Cellular Information Processing
|9 G:(DE-HGF)POF4-5244
|x 1
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-19
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-19
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-19
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS RES THER : 2022
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:32:54Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:32:54Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2024-04-10T15:32:54Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-13
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-13
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ALZHEIMERS RES THER : 2022
|d 2024-12-13
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
920 1 _ |0 I:(DE-Juel1)IBI-7-20200312
|k IBI-7
|l Strukturbiochemie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a I:(DE-Juel1)IBI-7-20200312
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21